On September 27, 2023, Biohaven unveiled an intriguing presentation outlining the latest pharmacodynamic updates for their ground-breaking drug, BHV-1300. This bispecific IgG degrader has shown remarkable potential, with repeat dosing resulting in astonishing reductions of over 90% in IgG levels. The comprehensive presentation, which can be found in a SEC filing, delves into the specifics of BHV-1300 starting from slide 57.
https://beststocks.com/title-biohaven-unveils-groundbreaking-pharmac/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.